Observational studyInternational ophthalmology2025
Salivary steroids in acute central serous chorioretinopathy.
Observational study in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hormonal factors in the pathophysiology of central serous chorioretinopathy - a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze levels of salivary steroids, including 17-OH-progesterone (17-OHP), androstenedione, dehydroepiandrosterone, cortisol, cortisone, progesterone, testosterone, and estradiol, in patients with acute central serous chorioretinopathy (CSCR) patients.
methodsAcute CSCR patients and healthy individuals were included in this observational case-control study. Levels of salivary steroids were determined by high-performance liquid chromatography with tandem mass spectrometry detection. Clinical characteristics of CSCR patients were assessed based on multimodal imaging.
resultsSeventeen CSCR patients (40.1 ± 4.6 years) and fourteen age-matched healthy controls (40.6 ± 3.8 years) were included. Mean central retinal thickness and subfoveal choroidal thickness in affected eye of CSCR patients were 436.2 ± 131.1 µm and 464.6 ± 132.6 µm, respectively. Mean best-corrected visual acuity was 0.09 ± 0.11 LogMAR. Mean symptoms duration before saliva collection was 0.9 ± 0.6 months. 17-OHP was decreased compared to the normal limits established in healthy controls in 10 out of 17 patients (59%), androstenedione in 15 out of 17 patients (88%), dehydroepiandrosterone in 10 out of 17 patients (59%), cortisol in 6 out of 17 patients (35%), cortisone in 12 out of 17 patients (83%), progesterone in 9 out of 17 patients (53%), testosterone in 10 out of 17 patients (59%), and estradiol in 5 out of 17 patients (29%). In total, among CSCR patients lower level in saliva was found for all studied hormones (p < 0.05), except progesterone and estradiol.
conclusionSalivary steroids are decreased in acute CSCR male patients compared with age-matched controls. This may indicate inhibition of steroidogenesis caused by chronic stress and personal reactivity preceding manifestation of CSCR.
Indexed as
Identifiers
39881075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.